Chickenpox: Clinical Trials

46 trials for Chickenpox, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

46 completed. 46 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 346Completed 46

Follow Chickenpox: new trials by email Literature Review of Chickenpox trials Research Report on Chickenpox

Trials (filtered) newest first · largest first

All 46 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines
Varicella Vaccine, Varivax - Varicella
Phase 3CompletedSinovac (Dalian) Vaccine Technology Co., Ltd.6422024-02-292025-01-27
Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old
Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd., Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd - Varicella
Phase 3CompletedShanghai Institute Of Biological Products24802022-02-132023-12-29
Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)
VARIVAX™ - Varicella
Phase 3CompletedMerck Sharp & Dohme LLC1502019-03-012021-04-06
An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization
Investigational live attenuated varicella vaccine - Varicella
Phase 3CompletedSinovac (Dalian) Vaccine Technology Co., Ltd.11932018-07-112021-12-09
Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)
VARIVAX® PE34 Process, VARIVAX® 2016 Commercial Process, M-M-R II® - Varicella
Phase 3CompletedMerck Sharp & Dohme LLC6002017-10-172021-01-27
A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines
Investigational live attenuated varicella vaccine, diluent of lyophilized vaccine - Varicella
Phase 3CompletedSinovac (Dalian) Vaccine Technology Co., Ltd.59972016-08-012017-10-26
Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age
NBP608, Varivax - Varicella
Phase 3CompletedSK Bioscience Co., Ltd.5162016-07-142019-05-08
A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.
Varilrix HSA-free, Varilrix™ - Chicken-pox Illness (Varicella Virus Disease), Chickenpox
Phase 3CompletedGlaxoSmithKline12362015-11-132019-11-25
Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.
MMR Bio-Manguinhos, MMR GlaxoSmithKline - Measles, Mumps
Phase 3CompletedThe Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)15602015-02-012016-07-11
A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella Vaccine
Vaccine manufactured at commercialized scale, Vaccine manufactured at trial-scale - Varicella
Phase 3CompletedSinovac (Dalian) Vaccine Technology Co., Ltd.11972014-04-072018-06-13
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
VARIVAX™ New Seed Process, VARIVAX™ 2007 process, M-M-R II™ - Varicella
Phase 3CompletedMerck Sharp & Dohme LLC6112014-03-072018-10-30
Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)
MMRV (AMP), MMRV (2006 process) - Measles, Mumps
Phase 3CompletedMerck Sharp & Dohme LLC14122012-06-052018-10-31
Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children
PriorixTetra™, Meningitec - Rubella, Varicella
Phase 3CompletedGlaxoSmithKline7162012-02-062018-08-17
Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV
JE-CV Vaccine, Varicella Vaccine - Japanese Encephalitis, Varicella
Phase 3CompletedSanofi Pasteur, a Sanofi Company4542010-08-252022-03-28
Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM
GSK Biological's investigational MMRV vaccine 208136, Priorix™, Varilrix™ - Varicella, Rubella
Phase 3CompletedGlaxoSmithKline4502009-11-092018-06-08
Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)
Varicella Virus Vaccine Live (2007 Process) (Oka/Merck), Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck), Measles, Mumps, and Rubella Virus Vaccine Live (MMR) - Varicella
Phase 3CompletedMerck Sharp & Dohme LLC5982009-01-012017-04-12
Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
PriorixTM, VarilrixTM, Priorix-Tetra® - Measles, Varicella
Phase 3CompletedGlaxoSmithKline4752008-10-012018-06-08
Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
MenACWY-CRM + MMRV, MMRV, MenACWY-CRM - Meningococcal Infections
Phase 3CompletedNovartis Vaccines16302008-02-012013-04-19
Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)
ProQuad® manufactured with recombinant Human Albumin (rHA) - Measles, Mumps
Phase 3CompletedMerck Sharp & Dohme LLC16202007-11-292018-01-30
Safety Study of ProQuad® rHA in Infants (V221-037)
ProQuad® - Measles, Mumps
Phase 3CompletedMerck Sharp & Dohme LLC33882007-10-242017-10-17

Showing 20 of 46. Sign in to see all of them.

Narrower conditions

Measles (25)  ·  Mumps (25)  ·  Rubella (25)  ·  Haemophilus Infections (4)  ·  Herpes Zoster (4)  ·  Meningitis, Meningococcal (3)  ·  AIDS-Related Complex (2)  ·  Acquired Immunodeficiency Syndrome (2)  ·  HIV Infections (2)  ·  Communicable Diseases (1)  ·  Diphtheria (1)  ·  Encephalitis, Japanese (1)  ·  Hepatitis B (1)  ·  Herpesviridae Infections (1)

Broader conditions

DNA Virus Infections (46)  ·  Infections (46)  ·  Varicella Zoster Virus Infection (46)  ·  Herpesviridae Infections (45)  ·  Virus Diseases (45)  ·  RNA Virus Infections (28)  ·  Mononegavirales Infections (25)  ·  Morbillivirus Infections (25)  ·  Mouth Diseases (25)  ·  Paramyxoviridae Infections (25)  ·  Parotid Diseases (25)  ·  Parotitis (25)  ·  Rubivirus Infections (25)  ·  Rubulavirus Infections (25)  ·  Salivary Gland Diseases (25)

Interventions

measles, mumps, rubella, varicella vaccine (14)  ·  Chickenpox Vaccine (6)  ·  Measles-Mumps-Rubella Vaccine (6)  ·  Herpes Zoster Vaccine (3)  ·  Meningococcal Vaccines (3)  ·  Heptavalent Pneumococcal Conjugate Vaccine (2)  ·  Priorix-Tetra vaccine (2)  ·  Vaccines, Attenuated (2)  ·  5-propynylarabinofuranosyluracil (1)  ·  Acyclovir (1)  ·  Adenosine Monophosphate (1)  ·  Desipramine (1)  ·  Duration of Therapy (1)  ·  Famciclovir (1)  ·  Hepatitis A Vaccines (1)

Sponsors

Merck Sharp & Dohme LLC (18)  ·  GlaxoSmithKline (11)  ·  Sanofi Pasteur, a Sanofi Company (4)  ·  Sinovac (Dalian) Vaccine Technology Co., Ltd. (4)  ·  Bristol-Myers Squibb (1)  ·  Glaxo Wellcome (1)  ·  National Center for Research Resources (NCRR) (1)  ·  Novartis (1)  ·  Novartis Vaccines (1)  ·  SK Bioscience Co., Ltd. (1)  ·  Shanghai Institute Of Biological Products (1)  ·  The Hospital for Sick Children (1)  ·  The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (1)

Countries

United States (8)  ·  Germany (7)  ·  China (3)  ·  Italy (3)  ·  Philippines (3)  ·  Czechia (2)  ·  Russia (2)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Canada (1)  ·  Chile (1)  ·  Costa Rica (1)  ·  Estonia (1)  ·  France (1)

Top investigators

Shengli Xia (2)  ·  Anne Fiquet, MD (1)  ·  Eliane Matos Santos (1)  ·  Nancy Nazaire Bermal, MD (1)  ·  Rommel Crisenio M. Lobo, MD (1)  ·  Shengli Xia, Master (1)  ·  Srinivasa N. Raja (1)  ·  Upton Allen (1)

Results publications

PMID 16452343, PMID 16567978, PMID 16804432, PMID 17502347, PMID 19273678, PMID 19366435, PMID 22123890, PMID 22406278, PMID 22772170, PMID 25765966, PMID 26362659, PMID 27149048, PMID 27423382, PMID 29087781, PMID 29325161, PMID 30481110, PMID 30616012, PMID 30765242, PMID 32429738, PMID 33736915, PMID 34473594, PMID 34702124, PMID 35632416

NIH funding

2004 (1), 2017 (1), 2019 (1)